China approves clinical trials of Sinopharm's Omicron-specific vaccine

A #Chinese inactivated #vaccine against #Omicron variants was approved for clinical trials by the National Medical Products Administration on Tuesday. The vaccine, developed by the China National Biotec Group affiliated with #Sinopharm, has been under research since December 2021, the company said.